Development of FabV inhibitors to combat drug-resistance in pathogenic Gram-negative bacteria KU Leuven
The bacterial type II fatty acid synthesis (FASII) pathway has been
recognized as an interesting and relatively underexplored target for
new antibacterials with a distinct mode of action. Among the
enzymes comprising this pathway, FabI, an enoyl-acyl carrier protein
reductase (ENR), was identified as the target of triclosan, one of the
most common additives to consumer products. In recent years, FabI
inhibitors ...